EUVIMEDEUVIMED entdecken
Crossref

Cadherin-17: A potential biomarker for early detection in pancreatic adenocarcinoma

William C Cho, Wing S Yu, Tsz C Hon, Elaine T Y Cheung, Xiao Q Wang, Dennis A Wong, Cesar S C Wong, Wah Cheuk, John M Luk

World Journal of Gastroenterology · 28.12.2026 · 32 (48)

DOI: 10.3748/wjg.121570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 28.12.2026. Verfasst von William C Cho und 8 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND The early detection of pancreatic adenocarcinoma remains a major clinical challenge. AIM To evaluate cadherin-17 (CDH17) as a potential diagnostic and prognostic biomarker for this malignancy. METHODS CDH17 expression was assessed in pancreatic tissue samples using immunohistochemistry quantified by the M-score method. This included 25 paired tumor and normal adjacent tissues, along with 22 healthy controls. Plasma levels of soluble CDH17 were measured in 242 samples (28 patients pre/post-treatment, 156 healthy controls) using an in-house immunoassay and compared to carbohydrate antigen 19-9 (CA19-9). RESULTS In tissue samples, CDH17 expression was significantly higher in cancer tissues compared to both normal adjacent tissues (P = 0.0005) and healthy controls (P = 0.000001). Analysis of 242 plasma samples showed that soluble CDH17 could distinguish early-stage cancer patients from healthy controls with 86% sensitivity and 86% specificity (area under the curve = 0.920). By contrast, CA19-9 demonstrated diagnostic value only in late-stage disease (area under the curve = 0.813). Prognostically, elevated CA19-9 was significantly associated with shorter survival (P = 0.0002), while patients with a high-CDH17/low-CA19-9 profile appeared to have more favorable outcomes in hypothesis-generating subgroup analyses. CONCLUSION CDH17 is consistently upregulated in pancreatic adenocarcinoma and it shows potential as a complementary biomarker to CA19-9, particularly for improving early detection. These findings warrant validation in larger, prospective cohorts.

Zitieren

APA

Cho, W. C., Yu, W. S., Hon, T. C., Cheung, E. T. Y., Wang, X. Q., Wong, D. A., Wong, C. S. C., Cheuk, W., & Luk, J. M. (2026). Cadherin-17: A potential biomarker for early detection in pancreatic adenocarcinoma. World Journal of Gastroenterology, 32(48). https://doi.org/10.3748/wjg.121570

Vancouver

Cho WC, Yu WS, Hon TC, Cheung ETY, Wang XQ, Wong DA, et al. Cadherin-17: A potential biomarker for early detection in pancreatic adenocarcinoma. World Journal of Gastroenterology. 2026;32(48). doi:10.3748/wjg.121570

BibTeX
@article{Cho2026,
  author = {Cho, William C and Yu, Wing S and Hon, Tsz C and Cheung, Elaine T Y and Wang, Xiao Q and Wong, Dennis A and Wong, Cesar S C and Cheuk, Wah and Luk, John M},
  title = {Cadherin-17: A potential biomarker for early detection in pancreatic adenocarcinoma},
  journal = {World Journal of Gastroenterology},
  year = {2026},
  volume = {32},
  number = {48},
  doi = {10.3748/wjg.121570}
}
Kostenlos starten →